Cover Image
市場調查報告書

全球非專利抗癌藥市場預測

Global Cancer Generics Market Forecast to 2022

出版商 RNCOS E-Services Pvt. Ltd. 商品編碼 310599
出版日期 內容資訊 英文 110 Pages
訂單完成後即時交付
價格
Back to Top
全球非專利抗癌藥市場預測 Global Cancer Generics Market Forecast to 2022
出版日期: 2016年10月10日 內容資訊: 英文 110 Pages
簡介

本報告提供全球非專利抗癌藥市場相關調查分析,市場現況與展望,包含各市場區隔的醫藥品趨勢,主要企業簡介等系統性資訊。

第1章 分析師的見解

第2章 調查手法

第3章 全球癌症治療藥市場預測

  • 癌症的發病率
  • 抗癌藥市場

第4章 市場成長因素與課題

  • 成長因素
  • 課題
  • 機會

第5章 全球非專利抗癌藥市場分析

第6章 全球非專利抗癌藥市場:各給藥途徑

  • 口服學名藥
    • Arimidex (Anastrozole)
    • Femara (Letrozole)
    • Hycamtin (Topotecan)
    • Stivarga (Regorafenib)
    • Tarceva (Erlotinib)
    • Xalkori (Crizotinib)
    • Xeloda (Capecitabine)
    • Gleevec/Glivec (Imatinib Mesylate)
    • Nolvadex (Tamoxifen Citrate)
    • Targretin (Bexarotene)
  • 注射學名藥
    • Camptosar (Irinotecan Hydrochloride)
    • Eloxatin (Oxaliplatin)
    • Gemzar (Gemcitabine Hydrochloride)
    • Navelbine (Vinorelbine Tartrate)
    • Platinol (Cisplatin)
    • Taxol (Paclitaxel)
    • Taxotere (Docetaxel)
    • Fusilev (Levoleucovorin)
    • Ellence (Epirubicin Hydrochloride)
    • Adriamycin (Doxorubicin Hydrochloride)

第7章 全球非專利抗癌藥市場:主要的各適應症

  • 肺癌
  • 乳癌
  • 大腸癌
  • 胃癌
  • 前列腺癌

第9章 趨勢與發展

第10章 M&A

第11章 主要企業

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

Within the pharmaceutical industry, the oncology market is growing at a rapid pace owing to the rising incidences of cancer. In 2015, 15.2 Million new cancer cases were registered across the globe. This number is forecasted to increase to a value of 19.3 Million by 2025. Furthermore, the patent expiry of blockbuster cancer drugs is another major factor which is propelling the growth of the cancer generics industry.

As per RNCOS report "Global Cancer Generics Market Forecast to 2022", the global cancer generics market is anticipated to witness a double digit growth during 2016-2022. This report provides a detailed analysis of the current and future market scenario of the global cancer generics market. The report provides insight about the major drivers and challenges, along with the latest trends and developments impacting the industry growth. In addition, the report also highlights various opportunities available for growth of the global cancer generics market.

The global cancer generics market has been segmented on the basis of mode of administration into oral and injectables. Injectables are the most widely used type of cancer generics drugs. The report also highlights the major cancer generic drugs available in the global market.

Furthermore, the global cancer generics market has also been segmented on the basis of the major indications they are used for. According to the report, breast cancer is expected to account for the largest share in 2016 due to presence of large number of generic drugs and rising incidences of this indication.

Based on geography, the report divides market into North America, Europe, and Asia-Pacific. In 2016, North America is estimated to account for the largest share. Moreover, the report also lists down various mergers and acquisitions taking place in the global generics industry.

The last section of the report discusses about the prominent players in global cancer generics market. A brief business overview and financial information about each of these players has been provided, along with their product portfolios. The recent development of every player has also been presented in the report. Overall, the research contains exhaustive information that will help clients in formulating market strategies and assessing opportunity areas in the global cancer generics market.

Table of Contents

1. Analyst View

2. Research Methodology

3. Global Cancer Drugs Market Outlook 2022

  • 3.1 Cancer Incidences
  • 3.2 Cancer Drug Market

4. Market Drivers & Challenges

  • 4.1 Drivers
    • 4.1.1 Increasing Cancer Incidences
    • 4.1.2 Strategic Collaborations
    • 4.1.3 Growing Geriatric Population
    • 4.1.4 Ability to Curb Healthcare Cost
  • 4.2 Challenges
    • 4.2.1 Growing Backlog of Generic Drug Applications
    • 4.2.2 Counterfeit Generic Drugs
  • 4.3 Opportunities
    • 4.3.1 Patent Expiry of Blockbuster Oncology Drugs
    • 4.3.2 Generic Cancer Drugs Made More Accessible to Developing Countries

5. Global Cancer Generics Market Analysis 2022

6. Global Cancer Generics Market by Mode of Administration

  • 6.1 Oral Generics
    • 6.1.1 Arimidex (Anastrozole)
    • 6.1.2 Femara (Letrozole)
    • 6.1.3 Hycamtin (Topotecan)
    • 6.1.4 Stivarga (Regorafenib)
    • 6.1.5 Tarceva (Erlotinib)
    • 6.1.6 Xalkori (Crizotinib)
    • 6.1.7 Xeloda (Capecitabine)
    • 6.1.8 Gleevec/Glivec (Imatinib Mesylate)
    • 6.1.9 Nolvadex (Tamoxifen Citrate)
    • 6.1.10 Targretin (Bexarotene)
    • 6.2 Injectables Generics
    • 6.2.1 Camptosar (Irinotecan Hydrochloride)
    • 6.2.2 Eloxatin (Oxaliplatin)
    • 6.2.3 Gemzar (Gemcitabine Hydrochloride)
    • 6.2.4 Navelbine (Vinorelbine Tartrate)
    • 6.2.5 Platinol (Cisplatin)
    • 6.2.6 Taxol (Paclitaxel)
    • 6.2.7 Taxotere (Docetaxel)
    • 6.2.8 Fusilev (Levoleucovorin)
    • 6.2.9 Ellence (Epirubicin Hydrochloride)
    • 6.2.10 Adriamycin (Doxorubicin Hydrochloride)

7. Global Cancer Generics Market by Major Indications

  • 7.1 Lung Cancer
  • 7.2 Breast Cancer
  • 7.3 Colorectal Cancer
  • 7.4 Stomach Cancer
  • 7.5 Prostate Cancer

8. Global Cancer Generics Market by Geographic Regions

  • 8.1 US
  • 8.2 Europe
  • 8.3 Asia-Pacific

9. Trends & Developments

  • 9.1 Generic Version of Blockbuster Cancer Drug
  • 9.2 Entry of Indian Generic Cancer Drug in US

10. Mergers & Acquisitions

11. Key Players

  • 11.1 Fresenius Kabi AG
  • 11.2 Pfizer Inc
  • 11.3 Teva Pharmaceutical Industries Ltd
  • 11.4 Mylan N.V
  • 11.5 Sun Pharmaceutical Industries Ltd
  • 11.6 Sandoz International GmbH - A Novartis Company
  • 11.7 Sanofi
  • 11.8 Dr. Reddy's Laboratories Ltd
  • 11.9 Cipla Ltd
  • 11.10 Apotex Inc

List of Figures:

  • Figure 3-1: Global - Cancer Incidences (Million), 2015 & 2025
  • Figure 3-2: Global - Cancer Incidences by Gender (Million), 2015
  • Figure 3-3: Global - Cancer Drugs Market (Billion US$), 2016 & 2022
  • Figure 4-1: Global - Cancer Incidences (Million), 2015, 2020, 2025 & 2030
  • Figure 4-2: Global - Cancer Mortality (Million), 2015, 2020, 2025 & 2030
  • Figure 4-3: Global - Population above 60 Years (Billion), 2013 & 2050
  • Figure 5-1: Global - Cancer Generics Market (Billion US$), 2016 & 2022
  • Figure 6-1: Global - Cancer Generics Market by Mode of Administration (%), 2016
  • Figure 7-1: Global - Cancer Generics Market by Major Indications (%), 2016
  • Figure 7-2: Global - Lung Cancer Generics Market (Billion US$), 2016 & 2022
  • Figure 7-3: Global -Lung Cancer Incidences (Million), 2015 & 2025
  • Figure 7-4: Global - Breast Cancer Generics Market (Billion US$), 2016 & 2022
  • Figure 7-5: Global -Breast Cancer Incidences (Million), 2015 & 2025
  • Figure 7-6: Global - Colorectal Cancer Generics Market (Billion US$), 2016 & 2022
  • Figure 7-7: Global -Colorectal Cancer Incidences (Million), 2015 & 2025
  • Figure 7-8: Global - Stomach Cancer Generics Market (Billion US$), 2016 & 2022
  • Figure 7-9: Global -Stomach Cancer Incidences (Million), 2015 & 2025
  • Figure 7-10: Global - Prostate Cancer Generics Market (Billion US$), 2016 & 2022
  • Figure 7-11: Global -Prostate Cancer Incidences (Million), 2015 & 2025
  • Figure 8-1: Global - Cancer Generics Market by Geographic Regions (%), 2016
  • Figure 8-2: US - Cancer Generics Market (Billion US$), 2016 & 2022
  • Figure 8-3: US - Cancer Incidences (Million), 2015 & 2025
  • Figure 8-4: Europe - Cancer Generics Market (Billion US$), 2016 & 2022
  • Figure 8-5: Europe - Cancer Incidences (Million), 2015 & 2025
  • Figure 8-6: Asia-Pacific - Cancer Generics Market (Billion US$), 2016 & 2022
  • Figure 8-7: Asia-Pacific - Cancer Incidences (Million), 2015 & 2025
  • Figure 11-1: Fresenius Kabi AG - Sales by Product Segment (%), 2015
  • Figure 11-2: Fresenius Kabi AG - Sales by Geographic Region (%), 2015
  • Figure 11-3: Pfizer Inc - Revenue by Business Segment (%), 2015
  • Figure 11-4: Pfizer Inc - Revenue by Geographic Region (%), 2015
  • Figure 11-5: Teva Pharmaceutical - Revenue by Business Segment (%), 2015
  • Figure 11-6: Teva Pharmaceutical - Revenue by Geographic Region (%), 2015
  • Figure 11-7: Mylan N.V. - Revenue by Business Segment (%), 2015
  • Figure 11-8: Mylan N.V. - Revenue by Geographic Region (%), 2015
  • Figure 11-9: Sun Pharmaceutical - Total Income by Business Segment (%), FY 2016
  • Figure 11-10: Sun Pharmaceutical - Total Income by Geographic Region (%), FY 2016
  • Figure 11-11: Sandoz International GmbH - Net Sales by Franchise (%), 2015
  • Figure 11-12: Sanofi - Sales by Business Segment (%), 2015
  • Figure 11-13: Sanofi - Sales by Geographic Region (%), 2015
  • Figure 11-14: Dr. Reddy's Laboratories - Revenue by Business Segment (%), FY 2016
  • Figure 11-15: Dr. Reddy's Laboratories - Revenue by Geographic Region (%), FY 2016
  • Figure 11-16: Cipla Ltd. - Revenue by Geographic Region (%), FY 2016

List of Tables:

  • Table 3-1: Most Prevalent Types of Cancer, 2015
  • Table 4-1: Global - Key Cancer Drugs and Patent Expiry Status
  • Table 6-1: List of Companies Dealing in Generic Arimidex
  • Table 6-2: Cost Comparison of Generics and Branded Arimidex (Anastrozole)
  • Table 6-3: List of Companies Dealing in Generic Femara
  • Table 6-4: Cost Comparison of Generics and Branded Femara (Letrozole)
  • Table 6-5: List of Companies Dealing in Generic Hycamtin
  • Table 6-6: List of Companies Dealing in Generic Xeloda
  • Table 6-7: Cost Comparison of Generics and Branded Xeloda (Capecitabine)
  • Table 6-8: List of Companies Dealing in Generic Gleevec
  • Table 6-9: Cost Comparison of Generics and Branded Gleevec (Imatinib Mesylate)
  • Table 6-10: List of Companies Dealing in Generic Nolvadex
  • Table 6-11: Cost Comparison of Generics and Branded Nolvadex (Tamoxifen Citrate)
  • Table 6-12: List of Companies Dealing in Generic Targretin
  • Table 6-13: List of Companies Dealing in Generic Camptosar
  • Table 6-14: Cost Comparison of Generics and Branded Camptosar (Irinotecan Hydrochloride)
  • Table 6-15: List of Companies Dealing in Generic Gemzar (Gemcitabine Hydrochloride)
  • Table 6-16: Cost Comparison of Generics and Branded Gemzar (Gemcitabine Hydrochloride)
  • Table 6-17: List of Companies Dealing in Generic Navelbine (Vinorelbine)
  • Table 6-18: Cost Comparison of Generics and Branded Navelbine (Vinorelbine)
  • Table 6-19: List of Companies Dealing in Generic Platinol (Cisplatin)
  • Table 6-20: List of Companies Dealing in Generic Taxol (Paclitaxel)
  • Table 6-21: Cost Comparison of Generics and Branded Taxol (Paclitaxel)
  • Table 6-22: List of Companies Dealing in Generic Taxotere (Docetaxel)
  • Table 6-23: Cost Comparison of Generics and Branded Taxotere (Docetaxel)
  • Table 6-24: List of Companies Dealing in Generic Fusilev (Levoleucovorin)
  • Table 6-25: List of Companies Dealing in Generic Ellence (Epirubicin Hydrochloride)
  • Table 6-26: List of Companies Dealing in Generic Adriamycin (Doxorubicin Hydrochloride)
  • Table 7-1: Global - Key Lung Cancer Drugs and Patent Expiry Status
  • Table 7-2: Global - Key Breast Cancer Drugs and Patent Expiry Status
  • Table 7-3: Global - Key Colorectal Cancer Drugs and Patent Expiry Status
  • Table 7-4: Global - Key Stomach Cancer Drugs and Patent Expiry Status
  • Table 7-5: Global - Key Prostate Cancer Drugs and Patent Expiry Status
  • Table 10-1: Global - Major M&A in the Generics Industry (2014-2016)
  • Table 11-1: Fresenius Kabi AG - Sales (Billion US$), 2013, 2014 & 2015
  • Table 11-2: Fresenius Kabi Pharmaceuticals - Key Cancer Generic Drugs
  • Table 11-3: Pfizer Inc - Revenue (Billion US$), 2013, 2014 & 2015
  • Table 11-4: Pfizer Inc - Key Cancer Generic Products
  • Table 11-5: Teva Pharmaceutical - Revenue (Billion US$), 2013, 2014 & 2015
  • Table 11-6: Teva Pharmaceutical - Key Cancer Generic Drugs
  • Table 11-7: Mylan N.V. - Revenue (Billion US$), 2013, 2014 & 2015
  • Table 11-8: Mylan N.V. - Key Cancer Generic Drugs
  • Table 11-9: Sun Pharmaceutical - Total Income (Billion US$), FY 2014, FY 2015 & FY 2016
  • Table 11-10: Sun Pharmaceutical - Key Cancer Generic Drugs
  • Table 11-11: Sandoz International GmbH - Sales (Billion US$), 2013, 2014 & 2015
  • Table 11-12: Sandoz International GmbH - Key Cancer Generic Drugs
  • Table 11-13: Sanofi - Net Sales (Billion US$), 2013, 2014 & 2015
  • Table 11-14: Sanofi - Key Cancer Generic Drugs
  • Table 11-15: Dr. Reddy's Laboratories - Revenue (Billion US$), FY 2014, FY 2015 & FY 2016
  • Table 11-16: Dr. Reddy's Laboratories - Key Cancer Generic Drugs
  • Table 11-17: Cipla Ltd. - Revenue (Billion US$), FY 2014, FY 2015 & FY 2016
  • Table 11-18: Cipla Ltd. - Key Cancer Generic Drugs
  • Table 11-19: Apotex Inc. - Key Cancer Generic Drugs
Back to Top